More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The company is planning to expand its plant capacity in in Vapi
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Dyslipidemia is a critical risk factor for cardiovascular diseases
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Subscribe To Our Newsletter & Stay Updated
